PremiumThe FlyAbivax assumed with an Equal Weight at Morgan Stanley Buy Rating for Abivax SA Driven by Promising Obefazimod Data and Market Potential Abivax’s Obefazimod: A Promising New Treatment for Ulcerative Colitis with Phase 3 Data Anticipated in 2025 PremiumCompany AnnouncementsAbivax Reports Strong Q3 Financials and Clinical Progress Abivax data support potential of obefazimod as UC treatment option Abivax SA Unveils New Ulcerative Colitis Treatment Data PremiumCompany AnnouncementsAbivax SA Reveals Soaring R&D Costs in H1 2024 Alphabet upgraded, Arm downgraded: Wall Street’s top analyst calls Abivax initiated with a Buy at Laidlaw 
